EAM
IMVT icon

Exome Asset Management’s Immunovant IMVT Stock Holding History

Exome Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-158,622
Closed -$4.03M – 67
2025
Q4 		$4.03M Hold
158,622
– – 1.93% 14
2025
Q3 		$2.56M Buy
+158,622
New +$2.57M 1.55% 27

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Exome Asset Management's IMVT Position: Q1 2026 in Review

Exome Asset Management sold out of Immunovant (IMVT) in Q1 2026, closing a stake of 158,622 shares — an estimated $4.03M sold.

Exome Asset Management first reported a position in IMVT in Q3 2025 and held it in 2 quarters. The position peaked at $4.03M in Q4 2025. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Exome Asset Management reported no remaining Immunovant position as of Q1 2026 after selling out during the quarter.
  • Exome Asset Management sold 158,622 Immunovant shares in Q1 2026, an estimated $4.03M.
  • Exome Asset Management first reported a position in Immunovant in Q3 2025 and held it in 2 quarters.
  • Exome Asset Management's Immunovant position peaked at $4.03M in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.